Cinnamon and COH in PCOS Women Underdoing IVF/ICSI Cycles

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-21

Study Completion Date

2026-02-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients with polycystic ovary syndrome, insulin resistance increases, and since the extracts from cinnamon reduces insulin resistance by two mechanisms (1- increasing activation of the IRS/PI-3 kinase insulin signaling pathway and 2- stimulate auto phosphorylation of the insulin receptor and inhibit protein tyrosine phosphatase I). Through these two mechanisms cinnamon extract make adipocytes to increase the glucose uptake and glycogen synthesis. So this hypothesis arises that it can be effective in improving the symptoms of polycystic ovary syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Cinnamon Extract on Insulin Resistance Parameters in Polycystic Ovary Syndrome: A Pilot Study

NCT00331279

Polycystic Ovary Syndrome

COMPLETED PHASE1

Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS)

NCT01483118

Polycystic Ovary Syndrome

COMPLETED PHASE3

The Effect of Cinnamon on Ovulation Induction in Women With Polycystic Ovary Syndrome

NCT03778099

Polycystic Ovary Syndrome Ovulation

COMPLETED PHASE3

Efficacy of Jianpi Qushi Huatan Decoction in the Treatment of Polycystic Ovary Syndrome

NCT05976295

Polycystic Ovary Syndrome

RECRUITING PHASE1/PHASE2

Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients

NCT01782911

Androgen Profile Inflammatory Markers IVF Outcome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This double-blind randomized clinical trial will be conducted in Royan Institute on patients with polycystic ovary syndrome undergoing in vitro fertilization cycle treatment to evaluate the effect of Cinnamon supplementation during controlled ovarian stimulation in patients with polycystic ovary syndrome.PCOS cases were diagnosed based on the Rotterdam criteria (4), and the presence of at least two of the following criteria: menstrual irregularity (cycle length \<26 days or \>35 days or variation between consecutive cycles of \>10 days); clinical (presence of hirsutism evaluated by a Ferriman- Gallwey score \>8, severe acne and alopecia) or biochemical (total testosterone concentration \>0.5 ng/ml and/or free testosterone\>3.5 pg/ml) hyperandrogenism; or ultrasound evidence of polycystic ovaries. Hirsutism was assessed according to the Ferriman-Gallwey-score and examination of nine body areas for coarse terminal hair, including upper lip, chin and chest, upper and lower areas of the abdomen, thighs and upper arms. In each part, the severity of hirsutism was graded from 1 to 4 and the participants with the total score of 8 and above considered as having hirsutism. PCOM was defined as the presence of 12 or more ovarian cysts with 2-10 mm diameter per ovary and/or ovarian volume ≥10 cm3. Vaginal ultrasound was performed by an ultrasound specialist and radiologist using an Aloka α-10 with a transvaginal 6-7.5 MHz probe (Medison Co., Japan).

The controlled ovarian stimulation method will be the same in all participants using the standard antagonist protocol. All patients diagnosed with polycystic ovary syndrome who are eligible based on the Rotterdam criteria and other inclusion and exclusion criteria stated in the general information section of the clinical trial and who have written consent to participate in the study will be examined. Patients will be randomly assigned into two groups using the block method in a size of 6, and each person will be given an exclusive code to keep the allocation hidden. The details of random allocation in terms of drug and placebo grouping are solely at the disposal of the project's pharmacist colleague, who have no role in the process of sampling and follow-up of patients.The medicine packages, as well as the appearance and smell of cinnamon and placebo tablets, are completely similar to each other. The methodologist prepared the drugs based on the block randomization method and prepared the coded list and put an English three-letter code label on the medicine cans. When an eligible patient is referred to a clinical physician, the principal investigator provides him with an envelope containing a drug code based on a randomized list, and the drug package with the same code is delivered to the patient. In this way, the patient and the clinical doctor following the patient will not know the type of drug (cinnamon or placebo).The method of ovarian stimulation and placebo consumption in the control group will be completely similar to the intervention group. In the intervention group, women will take 1500 mg daily (3500 mg cinnamon tablets, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process. Control group: patients take 3 placebo pills daily (containing white wheat flour, which is similar to cinnamon pills in terms of size, shape, color and smell, Sagepad Darou Pharmaceutical Company, Iran) 4 weeks before starting the ovarian stimulation/in vitro fertilization (COS/IVF) cycle and 2 weeks during the ovarian stimulation procedure, the ovary will be stimulated. Total number of retrieved oocytes and total number of MII oocytes will be compared between groups as primary outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycystic Ovary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cinnamon supplementation

In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.

Group Type EXPERIMENTAL

Oral cinnamon supplementation

Intervention Type DIETARY_SUPPLEMENT

In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.

Control group

Patients take 3 placebo pills daily (containing white wheat flour, which is similar to cinnamon pills in terms of size, shape, color and smell, Sagepad Darou Pharmaceutical Company, Iran) 4 weeks before starting the ovarian stimulation/in vitro fertilization (COS/IVF) cycle and 2 weeks during the ovarian stimulation procedure, the ovary will be stimulated

Group Type PLACEBO_COMPARATOR

Oral cinnamon supplementation

Intervention Type DIETARY_SUPPLEMENT

In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral cinnamon supplementation

In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infertile women with polycystic ovary syndrome (PCOS) diagnosed according to the Rotterdam criteria who meet at least 2 of the following three criteria including: (1) oligomenorrhea or anovulation, (2) hyperandrogenism (clinical or biochemical ng/ dL 80 ≤ serum T level), (3) the presence of polycystic ovaries in ultrasound).
* The age range of 18 to 38 year.
* Written consent to participate in the study

Exclusion Criteria

* Body mass index above 35 kg/m2
* Chronic and Endocrine disorders including diabetes mellitus, hyperprolactinemia, hypertension, Cushing's syndrome
* Autoimmune disorders
* History of recurrent pregnancy loss
* Genital, ovarian or uterine abnormalities
* Hydrosalpinx diagnosis
* Congenital adrenal hyperplasia, androgen-producing tumors or acromegaly
* Sensitivity to cinnamon
* Daily and frequent consumption of cinnamon to treat infertility
* Severe male factor infertility
* Moderate to severe endometriosis diagnosis Use of other hypoglycemic, insulin-sensitizing drugs (e.g. Metformin) or other antioxidant supplement (e.g. Myo-inositol) and β-blocker before or during the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

38 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No